Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | BCR | P11274 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | TEC | P42680 | 2/20 | 0.45 |
| ▸ | TXK | P42681 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22940380 | 1.00 | BTK (0.56) | BTKCRBNHDAC6ABL1BCR | |
| SCHEMBL22940938 | 0.99 | BTK (0.56) | BTKCRBNHDAC6ABL1BCR | |
| SCHEMBL22940927 | 0.91 | BTK (0.66) | BTKCRBNHDAC6EGFRTEC | |
| SCHEMBL22940204 | 0.91 | BTK (0.66) | BTKCRBNHDAC6EGFRTEC | |
| SCHEMBL22940352 | 0.91 | BTK (0.66) | BTKCRBNHDAC6EGFRTEC | |
| SCHEMBL22940928 | 0.91 | BTK (0.66) | BTKCRBNHDAC6EGFRTEC | |
| SCHEMBL22940937 | 0.91 | BTK (0.66) | BTKCRBNHDAC6EGFRTEC | |
| SCHEMBL22940862 | 0.91 | BTK (0.66) | BTKCRBNHDAC6EGFRTEC | |
| SCHEMBL22940354 | 0.91 | BTK (0.65) | BTKCRBNEGFRTECTXK | |
| SCHEMBL22940226 | 0.89 | BTK (0.62) | BTKEGFRTECTXKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281876-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2022-09-08 | — | — | US | disclosed |
| WO-2021018018-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281876-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | BTK 1/4885CRBN 84/4885HDAC6 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.